Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › HIV-1 Infection

HIV-1 Infection

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HIV-1 Infection

141 trials tracked for HIV-1 Infection: 50 in phase 3 or 4 and 28 with published results. The most-cited published study has 394 citations.

141Trials tracked
50Phase 3 & 4
0Recruiting
28With published results
Phase distribution
Phase 4 14 Phase 3 36 Phase 2 47 Phase 1 23 Other / NA 21
  1. Phase 3 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed · 394 cited
  2. Phase 3 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed · 379 cited
  3. Phase 3 Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed Completed · 201 cited
  4. Phase 3 Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults Completed · 179 cited
  5. Phase 3 Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF Completed · 165 cited
  6. Phase 3 Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC Completed · 160 cited
Show 44 more trials
  1. Phase 3 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed Completed · 112 cited
  2. Phase 4 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Completed · 108 cited
  3. Phase 3 Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) Completed · 94 cited
  4. Phase 3 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Completed · 91 cited
  5. Phase 3 Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Completed · 76 cited
  6. Phase 4 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Completed · 56 cited
  7. Phase 3 Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women Completed · 56 cited
  8. Phase 3 Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years Completed · 50 cited
  9. Phase 3 Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults Completed · 48 cited
  10. Phase 3 Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants Completed · 44 cited
  11. Phase 3 Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years Completed · 43 cited
  12. Phase 3 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Completed · 36 cited
  13. Phase 3 PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) Completed · 34 cited
  14. Phase 3 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis Completed · 33 cited
  15. Phase 3 Improving Pregnancy Outcomes With Progesterone Completed · 28 cited
  16. Phase 4 A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women Completed · 12 cited
  17. Phase 4 Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 Completed · 7 cited
  18. Phase 3 Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I Completed · 7 cited
  19. Phase 3 Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment Completed · 6 cited
  20. Phase 3 Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) Completed · 6 cited
  21. Phase 3 Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N Completed · 6 cited
  22. Phase 3 Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) Completed
  23. Phase 4 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults Completed
  24. Phase 4 FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Completed
  25. Phase 4 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed
  26. Phase 4 Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated Completed
  27. Phase 4 Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Completed
  28. Phase 4 B/F/TAF Switch Study for HIV-HBV Coinfection Completed
  29. Phase 4 Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine Completed
  30. Phase 4 Effect of Methamphetamine on Residual Latent HIV Disease Study Completed
  31. Phase 4 Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients Completed
  32. Phase 4 Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) Completed
  33. Phase 3 Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults Completed
  34. Phase 3 A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 Completed
  35. Phase 3 Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals Completed
  36. Phase 3 Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Completed
  37. Phase 3 PRO 140 in Treatment-Experienced HIV-1 Subjects Completed
  38. Phase 3 Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection Completed
  39. Phase 3 Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF Completed
  40. Phase 3 Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed
  41. Phase 3 Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression Completed
  42. Phase 3 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed
  43. Phase 3 HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults Completed
  44. Phase 3 Study of Options for Second-Line Effective Combination Therapy (SELECT) Completed

Showing the 50 most-cited and recently-updated of 141 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection
Genetics & Precision Medicine Cohort
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection New gene signature can spot Ebola infection in blood samples
This observational cohort study analyzed RNA-Seq data from nonhuman primates and human cohorts with Ebola virus infection and comparator inf…
Researchers found a 50-gene signature that reliably separates Ebola from other infections in blood tests, pointing to a future diagnostic to…
Frontiers Apr 23, 2026
HIV-2 infection shows lower viral loads and slower disease progression than HIV-1 in observational review
Allergy & Immunology Cohort
HIV-2 infection shows lower viral loads and slower disease progression than HIV-1 in observational review Why Some People Control HIV Without Meds: The Surprising Clue Scientists Are Using
This observational review compares HIV-2 and HIV-1 infection.
A different type of HIV shows the body can control the virus long-term, offering new hope for the 40 million people living with HIV worldwid…
Frontiers Apr 19, 2026
In silico analysis compares HIV-1 ENV CD8+ T cell epitopes restricted by HLA alleles A*01:01 and B*07:02 against bNAb targets
Pediatrics Guideline
In silico analysis compares HIV-1 ENV CD8+ T cell epitopes restricted by HLA alleles A*01:01 and B*07:02 against bNAb targets Why Your Body's Best Defense Might Be a Team Effort
This in silico analysis and literature review evaluated 1820 HIV-1 ENV peptides overlapping clades A and D.
A genetic marker linked to slower HIV infection triggers fewer T cell responses, suggesting quality matters more than quantity in immune def…
Frontiers Apr 14, 2026
HIV-2 diagnoses remain low in the United States, differentiation test use studied
Allergy & Immunology
HIV-2 diagnoses remain low in the United States, differentiation test use studied HIV-2 diagnoses remain low in the United States, report finds
A U.S. report on trends in HIV-2 diagnoses and HIV-1/HIV-2 differentiation test use found diagnoses of HIV-2 remain low.
HIV-2 diagnoses stay low in the U.S., but current testing methods could be updated to work better.
CDC Apr 4, 2026

Questions about HIV-1 Infection

Which HIV-1 infection strains are being analyzed in the current research studies?

Current research analyzes HIV-1 strains like CRF_35AD in Iran, CRF01_AE in Shanghai, and R5/X4 tropism variants for drug treatment, while HIV-2 is studied as a slower-progressing comparator.

Full answer →
How is HIV-1 infection differentiated from HIV-2 using specific medical tests?

Doctors differentiate HIV-1 from HIV-2 using specific antibody tests like the Geenius or cobas assays, which can identify the virus type based on unique antibodies and genetic markers.

Full answer →
How does HIV-1 infection compare to HIV-2 regarding disease progression speed?

HIV-2 infection generally progresses much slower than HIV-1, with lower viral loads and a significantly reduced risk of developing AIDS within the first five years.

Full answer →